Combination strategies to durably suppress HIV-1: Soluble T cell receptors

Wallace, Zoë; Singh, Praveen; Dorrell, Lucy

doi:10.1016/j.jve.2022.100082

Cited by 5 publications

(4 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immune-based therapies involve HIV neutralization or improved immune responses against the virus by the use of antibodies or other immunological-based medicines. [22]…”

Section: Inherent Need For Alternative Hiv Treatment Approachesmentioning

confidence: 99%

Toward a cure – Advancing HIV/AIDs treatment modalities beyond antiretroviral therapy: A Review

Alum,

Uti,

Ugwu

et al. 2024

Medicine

View full text Add to dashboard Cite

Antiretroviral therapy, also known as antiretroviral therapy (ART), has been at the forefront of the ongoing battle against human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDs). ART is effective, but it has drawbacks such as side effects, medication resistance, and difficulty getting access to treatment, which highlights the urgent need for novel treatment approaches. This review explores the complex field of HIV/AIDS treatment, covering both established alternative treatment modalities and orthodox antiretroviral therapy. Numerous reliable databases were reviewed, including PubMed, Web of Science, Scopus, and Google Scholar. The results of a thorough literature search revealed numerous therapeutic options, including stem cell transplantation, immunotherapy, gene therapy, latency reversal agents, and pharmaceutical vaccinations. While gene therapy has promise for altering cellular resistance to infection and targeting HIV-positive cells, immunotherapy treatments seek to strengthen the immune system’s ability to combat HIV. Latency reversal agents offer a promising method of breaking the viral latency and making infected cells vulnerable to immune system destruction or antiretroviral drugs. Furthermore, there is potential for improving immune responses against HIV using medical vaccinations. This review stresses the vital significance of ongoing research and innovation in the hunt for a successful HIV/AIDS treatment through a thorough examination of recent developments and lingering challenges. The assessment notes that even though there has been tremendous progress in treating the illness, there is still more work to be done in addressing current barriers and investigating various treatment options in order to achieve the ultimate objective of putting an end to the HIV/AIDS pandemic.

show abstract

“…Immune-based therapies involve HIV neutralization or improved immune responses against the virus by the use of antibodies or other immunological-based medicines. [22]…”

Section: Inherent Need For Alternative Hiv Treatment Approachesmentioning

confidence: 99%

Toward a cure – Advancing HIV/AIDs treatment modalities beyond antiretroviral therapy: A Review

Alum,

Uti,

Ugwu

et al. 2024

Medicine

View full text Add to dashboard Cite

show abstract

“…Therapeutic ImmTAC molecules targeting other tumor antigens PRAME, PIWIL1, or MAGE‐A4 in the complexes of HLA‐A2 or A24 have been recently developed, and some of these agents have entered clinical trials. Others target viral epitopes such as hepatitis B virus (HVB) and human immunodeficiency virus (HIV) 103,104 . As a therapeutic class, ImmTACs offer a tailored, off‐the‐shelf solution possessing high specificity, in turn mediating efficacious cancer cell cytotoxicity.…”

Section: Soluble Tcr‐based Therapiesmentioning

confidence: 99%

Challenges and solutions for therapeuticTCR‐based agents

Malviya

Aretz

Molvi

et al. 2023

Immunological Reviews

View full text Add to dashboard Cite

SummaryRecent development of methods to discover and engineer therapeutic T‐cell receptors (TCRs) or antibody mimics of TCRs, and to understand their immunology and pharmacology, lag two decades behind therapeutic antibodies. Yet we have every expectation that TCR‐based agents will be similarly important contributors to the treatment of a variety of medical conditions, especially cancers. TCR engineered cells, soluble TCRs and their derivatives, TCR‐mimic antibodies, and TCR‐based CAR T cells promise the possibility of highly specific drugs that can expand the scope of immunologic agents to recognize intracellular targets, including mutated proteins and undruggable transcription factors, not accessible by traditional antibodies. Hurdles exist regarding discovery, specificity, pharmacokinetics, and best modality of use that will need to be overcome before the full potential of TCR‐based agents is achieved. HLA restriction may limit each agent to patient subpopulations and off‐target reactivities remain important barriers to widespread development and use of these new agents. In this review we discuss the unique opportunities for these new classes of drugs, describe their unique antigenic targets, compare them to traditional antibody therapeutics and CAR T cells, and review the various obstacles that must be overcome before full application of these drugs can be realized.

show abstract

“…Other reviews focus on interventions that rely on the presence of HIV antigen like broadly neutralizing anti-HIV-1 antibodies (bNAbs) and bispecific molecules. 2 , 3 …”

Section: Immunomodulation In the Presence Or Absence Of Antigenmentioning

confidence: 99%

Immunomodulation with IL-7 and IL-15 in HIV-1 infection

Gunst,

Goonetilleke,

Rasmussen

et al. 2023

Journal of Virus Eradication

View full text Add to dashboard Cite

Combination strategies to durably suppress HIV-1: Soluble T cell receptors

Cited by 5 publications

References 64 publications

Toward a cure – Advancing HIV/AIDs treatment modalities beyond antiretroviral therapy: A Review

Toward a cure – Advancing HIV/AIDs treatment modalities beyond antiretroviral therapy: A Review

Challenges and solutions for therapeuticTCR‐based agents

Immunomodulation with IL-7 and IL-15 in HIV-1 infection

Contact Info

Product

Resources

About